Climb Bio (CLYM) News Today $1.30 -0.04 (-2.99%) As of 04/24/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Climb Bio (NASDAQ:CLYM) Trading Down 2.4% - Should You Sell?Climb Bio (NASDAQ:CLYM) Stock Price Down 2.4% - What's Next?April 24 at 4:39 AM | marketbeat.comExec Edge Launches Research Coverage with Initiation Notes on FLD, CLYM, STKS, REXApril 10, 2025 | finance.yahoo.comClimb Bio appoints Kim Cobleigh Drapkin, Bo Cumbo to boardApril 2, 2025 | markets.businessinsider.comQ2 Earnings Estimate for Climb Bio Issued By Leerink PartnrsClimb Bio, Inc. (NASDAQ:CLYM - Free Report) - Investment analysts at Leerink Partnrs upped their Q2 2025 earnings per share estimates for Climb Bio in a research report issued on Tuesday, March 25th. Leerink Partnrs analyst T. Smith now expects that the company will post earnings of ($0.15) per sMarch 29, 2025 | marketbeat.comClimb Bio Fueled Up with Cash, Poised for More Milestones in ’25 – Quarterly Update ReportMarch 27, 2025 | finance.yahoo.comClimb Bio to Present at the 24th Annual Needham Virtual Healthcare ConferenceMarch 27, 2025 | globenewswire.comClimb Bio Advances Clinical Trials and Expands PipelineMarch 27, 2025 | tipranks.comClimb Bio (NASDAQ:CLYM) Releases Earnings Results, Beats Estimates By $0.02 EPSClimb Bio (NASDAQ:CLYM - Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.15) by $0.02.March 26, 2025 | marketbeat.comClimb Bio, Inc.: Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business UpdatesMarch 26, 2025 | finanznachrichten.deClimb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business UpdatesMarch 25, 2025 | globenewswire.comClimb Bio: Meet The Newest Star in Autoimmune Disease Treatment – Initiation ReportMarch 20, 2025 | finance.yahoo.comClimb Bio (CLYM) Expected to Announce Earnings on ThursdayClimb Bio (NASDAQ:CLYM) will be releasing earnings before the market opens on Thursday, March 27, Financial Modeling Prep reports.March 20, 2025 | marketbeat.comClimb Bio (NASDAQ:CLYM) Shares Down 6.9% - Should You Sell?Climb Bio (NASDAQ:CLYM) Trading Down 6.9% - What's Next?March 4, 2025 | marketbeat.comClimb Bio to Present at Upcoming Investor ConferencesFebruary 25, 2025 | globenewswire.comClimb Bio appoints Perrin Wilson as CBOFebruary 24, 2025 | markets.businessinsider.comClimb Bio Appoints Perrin Wilson, Ph.D., as Chief Business OfficerFebruary 24, 2025 | globenewswire.comCLYM Stock Touches 52-Week Low at $1.5 Amid Market ChallengesFebruary 12, 2025 | msn.comClimb Bio FY2025 EPS Forecast Decreased by Leerink PartnrsClimb Bio, Inc. (NASDAQ:CLYM - Free Report) - Equities researchers at Leerink Partnrs lowered their FY2025 earnings estimates for shares of Climb Bio in a report issued on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now forecasts that the company will earn ($0.66) per share for theFebruary 10, 2025 | marketbeat.comLeerink Partnrs Comments on Climb Bio FY2029 EarningsClimb Bio, Inc. (NASDAQ:CLYM - Free Report) - Research analysts at Leerink Partnrs issued their FY2029 earnings estimates for Climb Bio in a report released on Wednesday, February 5th. Leerink Partnrs analyst T. Smith anticipates that the company will post earnings of ($2.73) per share for the yeFebruary 7, 2025 | marketbeat.comClimb Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceFebruary 4, 2025 | globenewswire.comClimb Bio (NASDAQ:CLYM) Trading Down 0.5% - Should You Sell?Climb Bio (NASDAQ:CLYM) Trading Down 0.5% - Time to Sell?January 23, 2025 | marketbeat.comLeerink Partners Sticks to Its Buy Rating for Climb Bio (CLYM)January 13, 2025 | markets.businessinsider.comClimb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA NephropathyJanuary 9, 2025 | globenewswire.comSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Climb Bio, Inc. (NASDAQ: CLYM)January 2, 2025 | prnewswire.comClimb Bio Inc (CLYM)December 30, 2024 | investing.comClimb Bio to be added to Nasdaq Biotechnology IndexDecember 20, 2024 | markets.businessinsider.comClimb Bio to be Added to the Nasdaq Biotechnology IndexDecember 19, 2024 | globenewswire.comLeerink Partnrs Comments on Climb Bio FY2024 EarningsClimb Bio, Inc. (NASDAQ:CLYM - Free Report) - Equities researchers at Leerink Partnrs issued their FY2024 earnings per share estimates for shares of Climb Bio in a research report issued on Monday, December 2nd. Leerink Partnrs analyst T. Smith expects that the company will post earnings per sharDecember 4, 2024 | marketbeat.com Get Climb Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for CLYM and its competitors with MarketBeat's FREE daily newsletter. Email Address CLYM Media Mentions By Week CLYM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CLYM News Sentiment▼0.000.73▲Average Medical News Sentiment CLYM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CLYM Articles This Week▼11▲CLYM Articles Average Week Get Climb Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for CLYM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Amylyx Pharmaceuticals News Today Mereo BioPharma Group News Today Altimmune News Today Checkpoint Therapeutics News Today Oruka Therapeutics News Today ORIC Pharmaceuticals News Today Erasca News Today Benitec Biopharma News Today Tectonic Therapeutic News Today Allogene Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CLYM) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredAmazon ShockerJeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Climb Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Climb Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CLYM Stock Free CLYM Stock Alerts